Show simple item record

dc.contributor.authorPaul, M J
dc.contributor.authorSummers, Yvonne J
dc.contributor.authorCalvert, A Hilary
dc.contributor.authorRustin, G J
dc.contributor.authorBrampton, M
dc.contributor.authorThatcher, Nick
dc.contributor.authorMiddleton, Mark R
dc.date.accessioned2009-09-07T12:38:24Z
dc.date.available2009-09-07T12:38:24Z
dc.date.issued2002-04
dc.identifier.citationEffect of temozolomide on central nervous system relapse in patients with advanced melanoma. 2002, 12 (2):175-8 Melanoma Res.en
dc.identifier.issn0960-8931
dc.identifier.pmid11930115
dc.identifier.urihttp://hdl.handle.net/10541/80033
dc.description.abstractTemozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS). Isolated CNS relapse is increasingly a problem for patients who respond to biochemotherapy. By replacing DTIC with temozolomide in treatment regimens, the incidence of CNS relapse might be reduced. This hypothesis is difficult to test in a prospective randomized controlled trial because of the large number of patients that would be required. We have examined this question in a retrospective case control study, observing the rates of CNS relapse in advanced metastatic melanoma patients responding to DTIC- or temozolomide-based chemotherapy in three institutions. Twenty-one DTIC and 20 temozolomide responders were identified, and have been followed up for a median of 19.0 months (range 6.0-74.3 months). CNS relapse occurred in nine DTIC- and two temozolomide-treated patients, a statistically significant difference in favour of the new agent (P = 0.03). These results support the investigation of temozolomide as a replacement for DTIC in systemic treatment regimens for melanoma.
dc.language.isoenen
dc.subjectBrain Canceren
dc.subjectLung Canceren
dc.subjectCancer Recurrenceen
dc.subjectCancer Stagingen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Agents, Alkylating
dc.subject.meshBrain Neoplasms
dc.subject.meshCase-Control Studies
dc.subject.meshDacarbazine
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMelanoma
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshNeoplasm Staging
dc.subject.meshRetrospective Studies
dc.subject.meshSoft Tissue Neoplasms
dc.subject.meshSurvival Rate
dc.subject.meshTreatment Outcome
dc.titleEffect of temozolomide on central nervous system relapse in patients with advanced melanoma.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalMelanoma Researchen
html.description.abstractTemozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS). Isolated CNS relapse is increasingly a problem for patients who respond to biochemotherapy. By replacing DTIC with temozolomide in treatment regimens, the incidence of CNS relapse might be reduced. This hypothesis is difficult to test in a prospective randomized controlled trial because of the large number of patients that would be required. We have examined this question in a retrospective case control study, observing the rates of CNS relapse in advanced metastatic melanoma patients responding to DTIC- or temozolomide-based chemotherapy in three institutions. Twenty-one DTIC and 20 temozolomide responders were identified, and have been followed up for a median of 19.0 months (range 6.0-74.3 months). CNS relapse occurred in nine DTIC- and two temozolomide-treated patients, a statistically significant difference in favour of the new agent (P = 0.03). These results support the investigation of temozolomide as a replacement for DTIC in systemic treatment regimens for melanoma.


This item appears in the following Collection(s)

Show simple item record